<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-92 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-92</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-92</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-fd8c293ec07c9a03f0de0c9eb752266f199977b1</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/fd8c293ec07c9a03f0de0c9eb752266f199977b1" target="_blank">A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.</a></p>
                <p><strong>Paper Venue:</strong> Genome Research</p>
                <p><strong>Paper TL;DR:</strong> It is demonstrated that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggested the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.</p>
                <p><strong>Cost:</strong> 0.022</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e92.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e92.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B-RET</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KIF5B-RET fusion gene</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A novel intrachromosomal fusion between KIF5B and the RET proto-oncogene generated by a ~10.6 Mb pericentric inversion on chromosome 10 that produces a chimeric protein containing the KIF5B coiled-coil dimerization domain fused to the RET tyrosine kinase domain; detected and validated by DNA/RNA sequencing and PCR/Sanger in multiple lung adenocarcinomas lacking canonical drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KIF5B-RET gene fusion (chromosomal inversion joining KIF5B exons to RET exon 12 with sample-specific breakpoints: AK55 KIF5B exon16 → RET exon12; LC_S2 KIF5B exon15 → RET exon12; LC_S6 KIF5B exon23 → RET exon12)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (chromosomal inversion)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KIF5B; RET (receptor tyrosine kinase ─ RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed in this study: 3/21 samples (AK55 + 20 replication = 14.3% observed); authors estimate population frequency ~6% (range 4.3%–8%) but note small sample size</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>Found in tumors lacking canonical drivers: AK55 (triple-negative) and in replication: 1/5 triple-negative and 1/15 double-negative primary LUADs; authors estimate ~4.3%–8% among driver-negative subsets (see text)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Whole-genome sequencing (DNA) showing inversion breakpoints, transcriptome sequencing (RNA-seq) showing high fusion transcript support, PCR and Sanger sequencing validation, exon-level expression analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Mechanistic inference: fusion transcript highly expressed with exclusive expression of RET kinase-domain exons (12–20) (~10× higher than controls), fusion preserves KIF5B coiled-coil dimerization domain and RET kinase domain (predicted to enable autophosphorylation and constitutive activation); paper infers transforming capacity but reports no in vitro/in vivo transformation assays in this manuscript.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected in a young (33 y), never-smoker patient with metastatic lung adenocarcinoma (AK55) and in additional primary tumors that were negative for EGFR/KRAS/ALK; associated with tumors lacking canonical EGFR/KRAS/EML4-ALK drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Authors propose the chimeric RET as a promising molecular target for personalized diagnosis and therapy; suggests potential sensitivity to RET-directed inhibitors though no drug-response data are reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>21 lung adenocarcinoma samples total (1 discovery case AK55 with deep WGS/RNA-seq + 20 primary tumors in replication study: 5 triple-negative and 15 double-negative by clinicopathologic testing)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing (DNA), transcriptome sequencing (RNA-seq), computational fusion detection (GFP/GSNAP), PCR and Sanger sequencing, exon-level expression (RPKM) analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e92.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor activating mutations (exons 18–21)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Well-established activating point mutations in EGFR kinase domain that drive a subset of lung adenocarcinomas (particularly in never-smokers and East Asians) and confer sensitivity to EGFR inhibitors; tested and absent in the discovery case AK55.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR activating mutations (mutations in exons 18–21, e.g., exon 19 deletions, L858R commonly reported in literature)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR (receptor tyrosine kinase ─ RTK → RAS/RAF pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>~15% (as cited in the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Prior literature (clinical studies) and clinical PCR/Sanger testing performed on study samples (AK55 negative)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Known to activate EGFR signaling and to confer sensitivity to EGFR tyrosine kinase inhibitors (e.g., gefitinib) as established in the literature (cited in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Enriched in never-smokers and East Asian patients; clinically actionable</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Patients with activating EGFR mutations often respond to EGFR-targeted therapies (gefitinib, erlotinib); mentioned as clinically relevant</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Screened in AK55 and in clinical pathological testing of other samples (methods describe PCR/sequencing of exon 18–21)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR and Sanger sequencing of EGFR exons 18–21 (clinicopathologic testing)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e92.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS oncogenic missense mutations (exon 2 / codons 12/13)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Common activating KRAS mutations in lung adenocarcinoma associated with smoking history and resistance to EGFR inhibitors; KRAS was assayed and not detected in the AK55 case.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS missense mutations (commonly in exon 2, codon 12/13)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS (RAS pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>~25% (as cited in the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Prior literature and routine clinical testing in this study (AK55 negative)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Oncogenic activation of RAS signaling; associated with primary resistance to EGFR-targeted therapies (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More common in smokers; confers poor response to EGFR inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Generally resistant to EGFR TKIs; therapeutic targeting is an area of research</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>KRAS exon 2 was tested in AK55 by PCR/Sanger; KRAS status unknown for some replication samples (not all were tested initially)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR and Sanger sequencing of KRAS exon 2 (clinicopathologic testing)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e92.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EML4-ALK fusion gene</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A recurrent fusion oncogene in NSCLC produced by inversion on chromosome 2 that defines an ALK-driven subset of lung adenocarcinomas and predicts response to ALK inhibitors; specifically tested and negative in AK55.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EML4-ALK gene fusion (chromosomal inversion)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EML4; ALK (anaplastic lymphoma kinase ─ RTK family)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>~5% (as cited in the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Literature precedent and clinical testing (FISH) in this study (AK55 negative)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Known to be transforming and sensitive to ALK inhibitors such as crizotinib (cited literature); no new functional assays reported in this manuscript.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More frequent in younger patients, never-smokers, and tumors negative for EGFR/KRAS (cited literature)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ALK-positive tumors respond to ALK inhibitors (crizotinib); referenced in the manuscript</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Tested by FISH in primary tissue of AK55 and in clinicopathologic workflows</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FISH for ALK rearrangement (clinicopathologic testing) and general transcriptome screening in replication</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e92.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RET proto-oncogene (tyrosine kinase) alterations / overexpression</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>RET is a known proto-oncogene (tyrosine kinase) with established roles in papillary thyroid carcinoma via fusion events; in this study RET kinase-domain exons (12–20) are highly expressed from the KIF5B-RET fusion, and the authors note RET overexpression in TCGA (3/32 samples).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RET kinase-domain overexpression and fusion to partner genes (here KIF5B-RET); RET rearrangements described in other cancers and implicated here as driver when fused</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>overexpression / gene fusion (context-dependent)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET (receptor tyrosine kinase ─ RTK)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>RET overexpression reported in TCGA data: 3/32 samples (9.4%) as noted by the authors</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Transcriptome expression analysis (this study) and TCGA expression data cited</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>In literature, RET fusions are transforming in other tumor types (papillary thyroid carcinoma); in this study RET kinase-domain is exclusively expressed from fusion transcripts and predicted to be activating via preserved kinase domain and partner dimerization domain.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Not previously highlighted in lung cancer; in this study associated with tumors lacking canonical EGFR/KRAS/ALK drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Authors propose RET-fusions as therapeutic targets; no clinical response data provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>TCGA observation cited: 32 samples for expression analysis; KIF5B-RET found in 3/21 study samples</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq exon-level expression analysis, comparison to TCGA expression profiles</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e92.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AK55 somatic mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ten somatic coding mutations identified in AK55 (8 SNVs, 2 indels)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Whole-genome sequencing of the AK55 liver metastasis identified 10 somatic coding changes (8 nonsynonymous SNVs and 2 coding indels) that were not located in canonical lung cancer driver genes and were predicted by SIFT to be unlikely drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>10 nonsynonymous somatic mutations (eight SNVs and two indels) identified in the metastatic cancer genome of AK55</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations and small indels (coding)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Various genes (none were in canonical drivers such as EGFR, KRAS, BRAF, PIK3CA, AKT1, MAP2K1, MET according to the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Whole-genome sequencing (tumor vs blood) and in silico functional annotation (SIFT)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>SIFT predictions and gene-function considerations led authors to conclude these are unlikely to be driver mutations; no functional assays reported.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Single case (AK55 discovery sample)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Deep whole-genome sequencing and variant calling (tumor-normal comparison)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e92.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Other fusion transcripts</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Set of 52 fusion transcript candidates identified in AK55 (majority intrachromosomal adjacents)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Transcriptome analysis identified 52 fusion transcript candidates in the AK55 liver metastasis sample; ~94% (49) are intrachromosomal fusions between adjacent genes (<135 kb) that are likely read-through or nonfunctional, and only KIF5B-RET had corroborating genomic rearrangement evidence.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Multiple candidate fusion transcripts (examples listed in Table 2 include KIF5B-KIAA1462, RPS6KB1-TMEM49, MIA2-CTAGE5, NKX2-1-SFTA3, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>fusion transcripts (predicted gene fusions; many likely read-throughs)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Various genes (mostly not in RTK/RAS/RAF pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Transcriptome sequencing (discordant paired-end reads and spanning reads) with computational filtering; only some validated by PCR</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Most candidates lacked genomic rearrangement support and are considered unlikely to be oncogenic in this study, except for KIF5B-RET which had genomic support; no functional characterization for these other fusions is reported.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Single discovery liver-metastasis sample (AK55)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>RNA-seq fusion detection (GSNAP/GFP), PCR validation for selected fusions</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e92.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e92.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Other known genes screened</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF, PIK3CA, AKT1, MAP2K1, MET (screened in AK55)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Authors report that the 10 somatic mutations found in AK55 did not occur in known driver genes such as BRAF, PIK3CA, AKT1, MAP2K1, and MET; these genes were considered in the analysis and no somatic driver mutations were found in them in AK55.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>No somatic mutations detected in BRAF, PIK3CA, AKT1, MAP2K1, MET in AK55</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation screening (negative findings)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF, PIK3CA, AKT1, MAP2K1, MET (MAPK/PI3K/RTK pathways)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>Whole-genome sequencing and targeted review of somatic calls in AK55</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Single case (AK55)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing and variant annotation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.', 'publication_date_yy_mm': '2012-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>New driver mutations in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer <em>(Rating: 2)</em></li>
                <li>RET and NTRK1 proto-oncogenes in human diseases <em>(Rating: 2)</em></li>
                <li>Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>